Figure S7 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Q: What type of study is this?

This is a Quantitative Study study.

Kristina Drizyte‐Miller; Lars D. Engstrom; Jeffrey A. Klomp; Clint A. Stalnecker; Addison G. Stamey; Khalilah E. Taylor; Mallory K. Roach; Ryan Robb; Laura Waters; Andrew Calinisan; Seamus Degan; Wen-Hsuan Chang; Xousaen M. Helu; David Nguyen; Elisa Baldelli; Mariaelena Pierobon; Emanuel F. Petricoin; David M. Briere; Jill Hallin; James G. Christensen; Kirsten L. Bryant; Adrienne D. Cox; Peter Olson; Channing J. Der

doi:10.1158/0008-5472.30125922

Key Points

The combination of PRMT5 and KRAS inhibitors effectively targets MTAP-deleted pancreatic cancer.
Gene splicing analysis using rMATS demonstrated significant changes in splicing patterns linked to treatment.
The approach was based on assessing combinatorial effects, focusing on specific genetic mutations.
This strategy could lead to improved outcomes for patients with specific pancreatic cancer mutations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Analysis reveals that combining PRMT5 inhibitors with KRAS inhibitors improves treatment effectiveness for pancreatic cancer, indicating new therapeutic strategies.

Abstract

Figure S7 shows gene splicing analysis using rMATS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Drizyte‐Miller et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa58865 https://doi.org/10.1158/0008-5472.30125922

View at Publisher

Ask AI

Bookmark

Share

Figure S7 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Figure S7 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading